Objectives: To ascertain predictors of initiation of brand-name versus generic narrow therapeutic index (NTI) drugs.
Design: Retrospective cohort study.
Setting: Data from CVS Caremark were linked to Medicare claims and to U.S. census data.
Participants: Individuals aged 65 and older who initiated an NTI drug in 2006 and 2007 (N = 36,832).
Measurements: Demographic, health service utilization, and geographic predictors of whether participants initiated a generic or brand-name version of their NTI drug were identified using logistic regression.
Results: Overall, 30,014 (81.5%) participants started on a generic version of their NTI drug. The most commonly initiated NTI drugs were warfarin (n = 17,790; 48%), levothyroxine (n = 10,779; 29%), and digoxin (n = 6,414; 17%). Older age (odds ratio (OR) = 1.12, 95% confidence interval (CI) = 1.02�1.22 comparing aged ?85 with 65�74), higher burden of comorbidity (OR = 1.05, 95% CI = 1.04�1.07 for each 1-point increase in comorbidity score), and prior use of any generic drug (OR = 1.55, 95% CI = 1.29�1.87) were positively associated with generic drug initiation. Independent of other predictors, residing in the census block group with the highest generic use was positively associated with greater odds of generic NTI drug initiation (OR = 1.24, 95% CI = 1.14�1.35 compared with the lowest quintile).
Conclusion: Demographic, health service utilization, and geographic characteristics are important determinants of whether individuals initiate treatment with a brand-name or generic NTI drug. These factors may contribute to disparities in care and highlight potential targets for educational campaigns.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados